CTOs on the Move

American Oriental Bioengineering

www.bioaobo.com

 
American Oriental Bioengineering is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.bioaobo.com
  • 15 Exchange Pl Ste 500
    Jersey City, NJ USA 07302
  • Phone: 646.367.1718

Executives

Name Title Contact Details

Similar Companies

Niadyne

Niadyne is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quincy Bioscience

Quincy Bioscience, LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Vision Partners

Our partner practices, including  Barnet Dulaney Perkins Eye Center, Southwestern Eye Center, Retinal Consultants of Arizona, M&M Eye Institute, Abrams Eye Institute, Havasu Eye Center and Visage Aesthetics and Plastic Surgery have on average been in p...

EDAP TMS

EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.